Lazou A, Fuller S J, Bogoyevitch M A, Orfali K A, Sugden P H
Department of Cardiac Medicine, National Heart and Lung Institute, University of London, United Kingdom.
Am J Physiol. 1994 Sep;267(3 Pt 2):H970-8. doi: 10.1152/ajpheart.1994.267.3.H970.
The coupling of the pharmacologically defined alpha 1A- and alpha 1B-adrenoceptors to the hydrolysis of phospho[3H]inositides (PI) was investigated in ventricular myocytes freshly isolated from adult rat hearts. The alpha 1-adrenoceptor population in the heart was characterized by competitive binding experiments using [3H]prazosin and the alpha 1A-adrenoceptor-selective antagonist 5-methyl urapidil. It was heterogeneous with approximately 25% being pharmacologically of the alpha 1A-adrenoceptor subtype and 75% being of the alpha 1B-adrenoceptor subtype. Epinephrine, norepinephrine, or phenylephrine stimulated PI hydrolysis in the presence or absence of propranolol. The greatest stimulation (7-fold) was with epinephrine. The half-maximum effective concentrations for agonists were approximately 0.5-3.5 and 0.2 microM in the absence and presence of propranolol, respectively. The inhibition by 5-methyl urapidil of the stimulation of PI hydrolysis by a fixed concentration of epinephrine fitted a two-site competition curve. The distribution between high-affinity (25%) and low-affinity (75%) sites suggested that both the alpha 1A- and alpha 1B-adrenoceptors were coupled to PI hydrolysis in proportion to their relative abundance. Equally, the stimulation of PI hydrolysis by epinephrine in the presence of a fixed concentration of 5-methyl urapidil was biphasic. In addition, chloroethylclonidine, an irreversible inhibitor of the alpha 1B-adrenoceptor, inhibited the epinephrine stimulation of PI hydrolysis by 35%. We conclude that the pharmacologically defined alpha 1A- and alpha 1B-adrenoceptor subtypes are both coupled to PI hydrolysis in the ventricular myocyte.
在从成年大鼠心脏新鲜分离的心室肌细胞中,研究了药理学定义的α1A - 和α1B - 肾上腺素能受体与磷酸[3H] - 肌醇(PI)水解的偶联。使用[3H]哌唑嗪和α1A - 肾上腺素能受体选择性拮抗剂5 - 甲基乌拉地尔通过竞争性结合实验对心脏中的α1 - 肾上腺素能受体群体进行了表征。它是异质性的,约25%在药理学上属于α1A - 肾上腺素能受体亚型,75%属于α1B - 肾上腺素能受体亚型。在存在或不存在普萘洛尔的情况下,肾上腺素、去甲肾上腺素或苯肾上腺素均刺激PI水解。最大刺激(7倍)是由肾上腺素引起的。在不存在和存在普萘洛尔的情况下,激动剂的半数有效浓度分别约为0.5 - 3.5和0.2 microM。5 - 甲基乌拉地尔对固定浓度肾上腺素刺激PI水解的抑制符合双位点竞争曲线。高亲和力(25%)和低亲和力(75%)位点之间的分布表明,α1A - 和α1B - 肾上腺素能受体均与其相对丰度成比例地与PI水解偶联。同样,在固定浓度的5 - 甲基乌拉地尔存在下,肾上腺素对PI水解的刺激是双相的。此外,α1B - 肾上腺素能受体的不可逆抑制剂氯乙可乐定抑制肾上腺素对PI水解的刺激达35%。我们得出结论,药理学定义的α1A - 和α1B - 肾上腺素能受体亚型均与心室肌细胞中的PI水解偶联。